Post Content
Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s latest stock calls as he shared how to navigate Wednesday’s tough tape. Cramer believes that the stock should have gone higher, as he stated:
What can you do on days like today? Well, the investing club… We like to buy, not big, but we’re not sellers. Why? Couple of reasons. We now think that Iran’s response could be more anemic than its previous barrage of pain. We’re going to find out soon enough though. We also like the stock market… when it’s oversold, -7 on the S&P Oscillator, that’s a key gauge that measures buying and selling pressure, and boy, that shows that there’s been way too much selling pressure.
Photo by Artem Podrez on Pexels
Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases. We recently talked about the stock while discussing Goldman Sachs top healthcare stocks, which you can read about here.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.